Health-related quality of life in Black breast cancer survivors with and without triple-negative breast cancer (TNBC)

Abstract

Purpose Black women are more likely to develop early onset (≤50 years) breast cancer (BC) and have the lowest five-year, cause-specific survival rate of any United States (U.S.) racial or ethnic group. These disparities can be attributed partially to the higher rate of triple negative BC (TNBC) in Blacks. Yet, little is known about health-related quality of life (HRQOL) among Black women with TNBC. Methods Black women with invasive BC ≤50 years were recruited via the Florida State Cancer Registry as part of a population-based case-only study of etiology and outcomes of early-onset invasive BC. Of 460 consented participants, a subset of 355 self-reported sociodemographic, clinical, and psychosocial variables were collected. Descriptive analyses included participants with known TNBC (n=85) or non-TNBC (n=245) disease. Univariable and multivariable analyses were conducted to examine differences in factors associated with HRQOL. Results In unadjusted analyses, TNBC participants had significantly lower FACT-B total scores (90.1 ± 27.9) compared to non-TNBC (98.5 ± 27.6) participants (p<0.05). For the TNBC group, multivariable analyses indicated five individual-level and three systemic-level factors explain 80% of the response variation in HRQOL. For the non-TNBC group, seven individual-level factors and three systemic-level factors account for 76% of the variation in HRQOL scores. Conclusions Compared to Black women with non-TNBC, TNBC women have worse HRQOL. There are key individual and systemic-level factors that are unique to both groups. Findings can inform future HRQOL interventions to support young Black BC survivors.

Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations

“…The onset of race-group mortality rate disparities coincides with the advent of hormone-targeted therapies [5] that are now standard-of-care for hormone receptor-positive tumors. Compared to women of European descent, AA women [4,[6][7][8][9][10][11][12][13] and women of African descent world-wide [9,[14][15][16] have a higher incidence of triple-negative breast cancer (TNBC) [17][18][19][20][21], which is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Therefore, in the context of standardizing ER/PR-and HER2-targeted therapies, the divergence of AA vs. EA mortality likely unmasked population-level differences in tumor biology, which we have previously shown to correlate with genetic ancestry [22].…”

Chemotherapy-Induced Peripheral Neurotoxicity as A Risk Factor for Poor Sleep Quality in Breast Cancer Survivors Treated with Docetaxel

“…Conversely, survivors with negative hormone and HER-2 (those with triple-negative breast cancer) may have relatively poor prognoses; thus, a study of survivors of triple-negative breast cancer found that they experienced significantly greater emotional distress and worry about their cancer than those who were diagnosed with a non-triple-negative breast cancer. [ 31 ] This finding, we suggest, may help to explain why, in this study, the survivors who received targeted therapy reported better sleep quality than those who received nontargeted therapy.…”

Qualidade de Vida de Mulheres Negras com Câncer de Mama: Uma Revisão de Literatura

“…Com relação à sobrevivência, é imprescindível assinalar que Samuel et al (2016), Pinheiro et al (2016), Pinheiro et al (2017), Vadaparampil et al (2017) e Claridy, Ansa, Damus, Alema-Mensah e Smith (2018) não concordaram quanto aos parâmetros temporais referentes a essa etapa da experiência oncológica. Seus estudos acataram desde o período de recebimento do diagnóstico até um período indeterminado que pode ser confundido com o próprio ciclo vital da paciente.…”